Hasil Pencarian - Yue‐Mei Hu

  • Menampilkan 1 - 10 hasil dari 10
Perbaiki Hasil
  1. 1
    Safety and immunogenicity of meningococcal (Groups A and C) polysaccharide vaccine in children 2 to 6 y of age in China: a randomized, active-controlled, non-inferiority study

    Safety and immunogenicity of meningococcal (Groups A and C) polysaccharide vaccine in children 2 to 6 y of age in China: a randomized, active-controlled, non-inferiority study oleh Feng-Cai Zhu, Yue-Mei Hu, Ya-Nan Li, Jean-Denis Shu, Philipp Oster

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    A comparative analysis of immunogenicity and safety of an enterovirus 71 vaccine between children aged 3-5 years and infants aged 6-35 months

    A comparative analysis of immunogenicity and safety of an enterovirus 71 vaccine between children aged 3-5 years and infants aged 6-35 months oleh Wei Gu, Gang Zeng, Yue-mei Hu, Yuan-Sheng Hu, Ying Zhang, Ya-ling Hu, Yang Wang, Jing-Xin Li, Feng-Cai Zhu

    Diterbitkan 2018-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Retraction note: TGF-β1-regulated miR-3691-3p targets E2F3 and PRDM1 to inhibit prostate cancer progression

    Retraction note: TGF-β1-regulated miR-3691-3p targets E2F3 and PRDM1 to inhibit prostate cancer progression oleh Yue-Mei Hu, Xiao-Li Lou, Bao-Zhu Liu, Li Sun, Shan Wan, Lei Wu, Xin Zhao, Qing Zhou, Mao-Min Sun, Kun Tao, Yong-Sheng Zhang, Shou-Li Wang

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    TGF-β1-regulated miR-3691-3p targets E2F3 and PRDM1 to inhibit prostate cancer progression

    TGF-β1-regulated miR-3691-3p targets E2F3 and PRDM1 to inhibit prostate cancer progression oleh Yue-Mei Hu, Xiao-Li Lou, Bao-Zhu Liu, Li Sun, Shan Wan, Lei Wu, Xin Zhao, Qing Zhou, Mao-Min Sun, Kun Tao, Yong-Sheng Zhang, Shou-Li Wang

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China

    Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-bli... oleh Shi-Yuan Wang, Shu-Zhen Liu, Kai Chu, Yue Zhao, Feng-Cai Zhu, Yue-Mei Hu, Fan-Yue Meng, Jing-Xin Li, Li Luo, Jia-Ying Yang, Pei Liu, Jun Yu

    Diterbitkan 2017-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals

    Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals oleh Xiao-Juan Yu, Juan Li, Zhi-Jie Lin, Hui Zhao, Bi-Zhen Lin, You-Lin Qiao, Yue-Mei Hu, Li-Hui Wei, Rong-Cheng Li, Wei-Dan Huang, Ting Wu, Shou-Jie Huang, Chang-Gui Li, Hui-Rong Pan, Jun Zhang

    Diterbitkan 2020-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Lot-to-lot consistency study of an Escherichia coli-produced bivalent human papillomavirus vaccine in adult women: a randomized trial

    Lot-to-lot consistency study of an Escherichia coli-produced bivalent human papillomavirus vaccine in adult women: a randomized trial oleh Ying-Ying Su, Bi-Zhen Lin, Hui Zhao, Juan Li, Zhi-Jie Lin, You-Lin Qiao, Li-Hui Wei, Yue-Mei Hu, Rong-Cheng Li, Si-Jie Zhuang, Guang Sun, Zi-Zheng Zheng, Shou-Jie Huang, Ting Wu, Jun Zhang, Hui-Rong Pan, Chang-Gui Li

    Diterbitkan 2020-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response

    Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response oleh Chun-Lan Zhuang, Zhi-Jie Lin, Zhao-Feng Bi, Ling-Xian Qiu, Fang-Fang Hu, Xiao-Hui Liu, Bi-Zhen Lin, Ying-Ying Su, Hui-Rong Pan, Tian-Ying Zhang, Shou-Jie Huang, Yue-Mei Hu, You-Lin Qiao, Feng-Cai Zhu, Ting Wu, Jun Zhang, Ning-Shao Xia

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial

    Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised,... oleh Jing-Xin Li, PhD, Li-Hua Hou, PhD, Fan-Yue Meng, MSc, Shi-Po Wu, PhD, Yue-Mei Hu, BS, Qi Liang, BS, Kai Chu, MSc, Zhe Zhang, BS, Jun-Jie Xu, PhD, Rong Tang, MSc, Wen-Juan Wang, MSc, Pei Liu, ProfPhD, Jia-Lei Hu, MSc, Li Luo, MSc, Rong Jiang, MSc, Feng-Cai Zhu, MSc, Wei Chen, PhD

    Diterbitkan 2017-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Efficacy, immunogenicity and safety of the AS04‐HPV‐16/18 vaccine in Chinese women aged 18‐25 years: End‐of‐study results from a phase II/III, randomised, controlled trial

    Efficacy, immunogenicity and safety of the AS04‐HPV‐16/18 vaccine in Chinese women aged 18‐25 years: End‐of‐study results from a phase II/III, randomised, controlled trial... oleh Feng‐Cai Zhu, Shang‐Ying Hu, Ying Hong, Yue‐Mei Hu, Xun Zhang, Yi‐Ju Zhang, Qin‐Jing Pan, Wen‐Hua Zhang, Fang‐Hui Zhao, Cheng‐Fu Zhang, Xiaoping Yang, Jia‐Xi Yu, Jiahong Zhu, Yejiang Zhu, Feng Chen, Qian Zhang, Hong Wang, Changrong Wang, Jun Bi, Shiyin Xue, Lingling Shen, Yan‐Shu Zhang, Yunkun He, Haiwen Tang, Naveen Karkada, Pemmaraju Suryakiran, Dan Bi, Frank Struyf

    Diterbitkan 2019-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: